BioLayer assays Prince of Wales
Wednesday, 10 September, 2008
BioLayer Corporation [ASX: BLS] has officially entered into a commercial agreement with the Prince of Wales Medical Research Institute.
The two organisations plan to collaborate on an assay and other diagnostic tools for use in the early detection of neurodegenerative diseases such as Parkinson's.
The companies will share IP to create the new detection tools. Under the agreement, BioLayer has the option to develop existing IP from the Prince of Wales under license.
BioLayer expects to exercise that option early next year.
BioLayer has also filed a patent application for a new approach to protecting assay processes for the early detection of neurodegenerative diseases.
Depression impacts energy at a cellular level, researchers find
Depression symptoms may be rooted in fundamental changes in the way brain and blood cells use...
Are discarded peanut shells the affordable and sustainable path to graphene?
Australian researchers have produced small quantities of high-quality graphene via a new process...
Aussie biotech to manufacture mRNA paediatric brain cancer vaccines
A Queensland-based biotechnology company will manufacture personalised mRNA paediatric brain...
